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le. For these reasons, OC are the contraceptive me-
thod of choice for the majority of Western world
women between the ages of 15 and 44 years1. 
Decision on giving OC to patients with Systemic
Lupus Erythematosus (SLE) puts special issues and
concerns. SLE is a chronic systemic autoimmune di-
sease which etiology probably involves a complex in-
teraction between environmental, infectious and
hormonal factors in a genetically susceptible sub-
ject2. Despite it can affect any gender at any age, SLE
is much more common among women and its inci-
dence is significantly increased during reproducti-
ve years. Among the risk factors for SLE OC have
been evocated as etiologic factors. During its cour-
se, SLE presents a wide range of manifestations al-
ternating periods of exacerbation and remission. OC
was also associated with an increased risk of flares
with variable severity. Other clinical problems with
higher occurrence among SLE patients as thrombo-
tic events can be potentiated when OC are used.
Being SLE a disease with major expression
among women, OC have been questioned for the-
se patients over time. During periods of active di-
sease pregnancy is contraindicated, due to risks for
the patient and the baby, associated both to SLE
and its treatment. For these cases, an effective con-
traception is mandatory but also puts special is-
sues. On the other hand, many SLE patients will be
on a low activity or remission state with much less
aggressive medication for most of the time. Cumu-
lative damage due to SLE and comorbidities such
as cardiovascular disease, antiphospholipid
syndrome antibodies also has to be considered for
pregnancy and contraception decisions. Physici-
ans who care of SLE women are commonly sub-
mitted to questions about these issues, not only for
their patients but also from other health professio-
nals. Advice on the benefits and risks of exogenous
hormones for OC is an important and difficult as-
pect of the care of women with SLE. This advice
should be done based on the best evidence from
Abstract
Oral contraceptives (OC) are the contraceptive me-
thod of choice for the majority of Western world
women. Decision on giving OC to patients with
Systemic Lupus Erythematosus (SLE) puts special
issues and concerns. In fact, OC have been evoca-
ted as etiologic risk factors for SLE and also asso-
ciated with an increased risk of flares. During pe-
riods of active disease an effective contraception is
mandatory, but OC puts safety problems in this set-
ting. On the other hand, many SLE patients will be
on a low activity or remission state with much less
aggressive medication for most of the time. Cumu-
lative damage due to SLE and comorbidities such
as cardiovascular disease, antiphospholipid
syndrome/ antibodies also has to be considered for
pregnancy and contraception decisions.
Advice on the benefits and risks of OC is an im-
portant and difficult aspect of the care of women
with SLE. This advice should be done based on the
best evidence and always considering our particu-
lar subject and its changing risk profile. This review
will focus on OC in SLE women and particularly on
current evidence on safety.
Keywords: Systemic Lupus Erythematosus; Con-
traception; Oral Contraceptives. 
Introduction 
During recent decades, generalized use of oral con-
traceptives (OC) by women gave them direct con-
trol of pregnancy issues and accounted to a social
revolution. Since the early days, OC had the charac-
teristic of being both the most convenient and ef-
fective non-surgical method of birth control (when
taken adequately) with an acceptable safety profi-
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available studies and always considering our par-
ticular subject and its changing risk profile.
This review will focus on contraception in SLE
women, regarding to their indications and poten-
tial risks for these particular patients. 
Hormonal Contraceptives
Hormonal contraceptives prevent conception
through a number of mechanisms. Ovulation is
prevented by inhibition of gonadotrophin secre-
tion via an effect on both pituitary and hypothala-
mic centers. Peripherally, estrogen provides endo-
metrial stability to prevent breakthrough bleeding.
Progesterone increases cervical mucus viscosity,
decreases tubal peristalsis and cilial action, and
diminishes the endometrial ability to support the
growth of an embryo3,4. Progestin affect and may
inhibit ovulation depending the dosage5. 
From the pharmacological point of view, hormo-
nal methods use either a combination of estrogen
and progestin or progestin only. Hormonal contra-
ceptives can be administered through different rou-
tes: oral, transdermal, intrauterine or intravaginal6.
The ethynilestradiol is the estrogenic component
of OC. During the last years there was a progressive
and significant reduction in its dose from almost 80
µg to as low as 15 µg. 17ß-estradiol has been used in
transdermal patches. With the development of injec-
tions with the duration of action of 1 month, two es-
ters of the natural hormone 17ß-estradiol (estradiol
cypionate and estradiol valerate) have been used6.
Currently, progestin employed in oral contra-
ceptives belongs to two main chemical families:
the first includes derivates from progesterone and
the second derivates of 19-nortestosterone or go-
nane6. Several formula combining estrogen and
progestin are available and new and old progestin
can be used (drospirenone, dienogest, chlormali-
done containing oral contraceptives). To avoid the
side effects due to the estrogen compound, proges-
tative only contraceptives have been developed.
At present the four most often used preparations
are desogestrel 75 µg, levonorgestrel 30 µg, nor-
gestrel 30 µg and the norethisterone 350 µg/day.
The newest desogestrel 75 µg presents the higher
efficacy to contraception with the longer safety
margin (12h) and less side effects5,7,8. Other pro-
gestins are used for injectable formula (depome-
droxyprogesterone) and implants (levonorgestrel,
etonogestrel, nestorone and nomegestrol)5,9,10. 
Why did physicians believe in a potential 
negative role of female hormones in SLE?
The inference that female hormones have an im-
portant role in SLE comes firstly from the highest
incidence and prevalence rates of this disease
among women reported over time. All studies in
SLE show a female predominance. In large cohorts
in Europe, USA and Latin America the majority of
subjects included are women (90.8%, 88% and 90%
respectively)11-13. When compared female to male
ratios, it varies between 4.3 and 11.7. The inciden-
ce is higher among women in all ages but the dif-
ference is greater in the 15-40 years old group, with
less differences in children and after 70 years of
age14-19. The peak incidence rate for women is du-
ring puberty and during the child bearing years,
suggesting an important role from sex hormones.
Experimental data with SLE models support this
association. Studies conducted in mouse model
SLE (NZB/NZW, MRL/1pr and BALB/c) show the
role of sex hormones and its receptors in SLE on-
set and development, showing an increased renal
disease associated with estrogen levels and that
androgens are protective20-25. 
Further evidence comes from human studies re-
porting abnormalities in sex hormones levels. An
increased level of estrogen and a low level of andro-
gens in women with SLE were reported26-28. The re-
sults in male are scarcer and usually the samples
are very small. Overall, significantly lower levels of
testosterone and dihydrotestosterone are found in
male SLE patients when compared with controls26,29. 
Furthermore, pregnancy is considered a poten-
tial trigger for SLE flare. High incidence of flares du-
ring pregnancy is reported in two prospective stu-
dies, mostly in the second trimester and post-par-
tum30,31. A retrospective case control-study also
shows a higher flare rate in the pregnant group
(0.093 of per patient per year) than among con-
trols (0.049 per-patient per-year). In this study, the
majority of flares occurred during the second and
third trimester and 8 weeks post deliver32. The in-
creased level of estrogen during pregnancy could
explain the risk of flare during this period and gave
physicians more reasons to believe in the risk as-
sociation between female hormones and SLE. 
Taking in consideration all these data, hormo-
ne therapy in women with SLE remains an impor-
tant concern to physicians. Observational and in-
terventional studies were conducted over time to
ascertain the role of estrogens in SLE and impro-
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ved evidence necessary for giving each patient the
better advice. 
Oral Contraceptives and the risk of SLE
The role of exogenous estrogens as a trigger of SLE
was the aim of different studies and controversial
results have been published over time (Table 1). 
A case control study from Sweden33, with 85 SLE
patients and 205 sex-age matched controls found
no association between OC containing estrogens
and SLE onset. No data related with other kind of
oral contraceptives or estrogens level was ana-
lyzed. These results were similar to a previous case
control study conducted by Strom et al34 in Phila-
delphia. In the Carolina Lupus Study, a population
based, case control study that assembled its sub-
jects by identifying 240 SLE patients from commu-
nity-based rheumatologists in South Carolina and
comparing them to control subjects through dri-
ver’s license records frequency-matched to cases
within 5 years of age, sex and state found no cor-
relation between OC and SLE35. The authors also
Table I. Evidence of risk of developing SLE associated with OC use
Author, year Contraceptive method Study design Results
Strom, 199434 OC unspecified Case control study No association between 
SLE: 195 OC´s and SLE
Controls: 143
Sanchez Guerrero, OC unspecified Prospective cohort study Past users vs never 
199736 NHS I (n=121 645) users: RR:1.9 (95% IC: 1.1-3.3)
No relation with duration of
OC
Bengtsson, 200233 OC containing estrogen Case control study No association between OC 
SLE: 85 and SLE
Controls: 205
Cooper, 200235 OC unspecified Population-based case No association between OC 
control study and SLE
N=240 female SLE
N= 320 female controls 
Costenbader, 200737 OC unspecified Cohort study Ever use of OC: RR: 1.5 
NHS I and NHSII (n=238,308) (95% IC: 1.1-2.1)
262 SLE female Highest risk with short 
duration (<2y) of OC (RR: 1.9,
95%IC: 1.3-2.8)
No association with kind of
OC
Bernier, 200938 OC Population based nested case Any use of OC
control-study (UK GPRD) RR: 1.19 (95% IC: 0.98-1.45)
SLE: 786 Current use of OC
Controls: 7817 RR: 1.54 (95% IC: 1.14-5.57)
Risk was higher:
- in current users who 
recently started (RR:2.52,
95% IC: 1.14-5.57)
- first or second generation
OC  increase with dose of
ethinylestradiol
NHS: Nurse Health Study; UK-GPRD: United Kingdom General Practice Registered Database
RR: Relative Risk, OR: Odds Ratio
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make reference that there was no association with
other hormonal contraceptives, however data re-
lated with this issue is not well clarified.
However, all previous studies were case control,
based in patients self report which is associated
with some limitations as bias, particularly selection
and recall bias or temporal relationship difficult to
establish. More recently, prospective studies using
large database were conducted. Cohort studies
provides some of the strongest evidence that a fac-
tor is important in a specific disease etiology with
establishment of temporal relationship, minimize
the bias risk and are considered the most adequa-
te epidemiologic studies. 
Prospective studies using the Nurses Health
Study cohort (NHS) report an association between
OC and SLE onset. Analyzing data from this 
cohort, past users of OC had an age and post-me-
nopausal hormones adjusted RR of developing SLE
of 1.4 (95% IC 0.9-2.1) compared with never users.
On the other hand, there was no significant increa-
sed risk with duration of OC use or time since first
or last use36. Furthermore, risk associated with to
type of hormonal contraceptive or estrogen level
was not evaluated.In a study conducted by Costen-
bader et al, using data from the same cohort, OC
were associated with an increased risk of develo-
ping SLE (RR 1.5; CI 95%: 1.1-2.1) but paradoxically
the risk was highest among women with shorter du-
ration of OC use, and no association was found with
type of hormones or the OC hormone potency37.
More recently, a population-based nested case
control study using the UK´s General Practice Rese-
arch Database, including 786 incident cases of SLE
and 7817 age matched controls, report an increased
risk of SLE onset associated with OC use (RR: 1.19).
The risk is greater with current use (RR: 1.54; 95% CI:
1.15-2.07), particularly among patients who had
only recently started OC (RR: 2.52; 95%CI: 1.14-5.57).
The risk appears to be particularly increased with
current exposure to first or second generation OC
(RR: 1.65; 95% CI: 1.20-2.96) and increasing with the
dose of ethinylestradiol, with a RR of 2.92 for OC
with 50 µg of ethinylestradiol compared to a RR of
1.42 when a dose of 30 µg is used38.
Oral contraceptives and disease activity in
SLE patients
Prescription of OC might be considered in SLE pa-
tients for several reasons. First, pregnancies and
conception planned during remission have better
outcomes. Secondly, most female SLE patients
would appreciate to be allowed such a convenient
contraceptive as OC, just like any other women.
Other rationale is that patients with very active di-
sease or those receiving potentially teratogenic
medications should use an extremely reliable form
of birth control. A side effect of cyclophosphami-
de, a common immune-suppressive therapy used
in SLE patients with active disease, is infertility.
Despite of actually only gonadotrophin-releasing
hormone analog show some evidence in reducing
the risk of ovarian failure associated with cyclo-
phospamide39 and no available data related with
OC protective role, it is believed that oral contra-
ceptives inhibiting ovulation can potentially miti-
gate infertility among cyclophosphamide users40. 
However, in SLE patients OC use was associated
over time with increased risk of SLE flare. Several
studies have addressed this issue (Table II).
A retrospective study conducted by Jungers et al,
with 60 SLE women with renal disease, show that
43% of patients experienced an exacerbation of lu-
pus nephritis when medicated with OC (estrogen
dosage from 30µg to 50 µg of ethinylestradiol) com-
pared to none exacerbations in control group (re-
ogestin-only OC or non-users)41. Another retros-
pective study based on self-report of flare showed
that 13% of patients referred occurrence of flare
after starting OC41. These results were contradicted
by other studies. Julkunken et al, in a retrospecti-
ve study, including 85 SLE patients found no sta-
tistically significant difference in the flare rate com-
paring Combination OC users and non-users43.
Studies with higher quality were later conducted to
clarify this issue. The Safety of Estrogen in Lupus
Erythematosus National Assessment (SELENA) is
a double blind randomized placebo-controlled
equivalence trial of OC therapy in pre-menopau-
sal women. The SELENA study included 183 pre-
menopausal women with inactive (76%) or stable
active (24%) SLE, who were randomly assigned to
receive either OC (triphasic ethinylestradiol 35 µg
plus norethindrone at a dose of 0.5 to 1 mg for 12
cycles of 28 days) or placebo. Demographic and
clinical characteristics were similar between
groups. No flare increase was observed in treated
patients compared to the placebo group. Discon-
tinuation rate due to any reasons (side effects,
pregnancy, voluntary or lost to follow up) was si-
milar between groups, as well as the 12-month non
adherence rate44. Sanchez-Guerrero et al conduc-
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ted a single-blind clinical trial involving 162 wo-
men with systemic lupus erythematosus without
active disease at baseline who were randomly as-
signed to combined OC (30 µg of ethinyl estradiol
plus 150 µg of levonorgestrel), a progestin-only pill
(30 µg of levonorgestrel) , or a copper intrauterine
device (IUD) (TCu 380A copper device). In this
study, disease activity remained mild and stable in
all groups throughout the trial. There were no sig-
nificant differences among the groups during the
trial in global or maximum disease activity, inci-
dence or probability of flares, or medication use.
The median time to the first flare was three months
in all groups45. In conclusion, available evidence
from randomized controlled trials support the sa-
fety of low-dose combined OC in SLE patients with
inactive or stable disease in regard to the risk of a
SLE flare. 
The first studies conducted in this area were
small, not randomized, confounders not conside-
red which limits their quality and makes it difficult
to interpret the results. Discrepancies between stu-
dies could be justified by different estrogens levels
with higher dosage in the early studies. Despite of
better design in the recent studies, with larger sam-
ples, generalization of their results is a limitation
(due to exclusion criteria) and its application in in-
dividual cases should be made carefully. As pati-
ents with active disease at baseline were excluded
in both trials, no data are available about security
of OC (even progestatin-only or combined pill) in
patients with active disease. 
Table II. Evidence of OC effect on SLE activity
Author, year Contraceptive method Study design Results
Jungers, 198240 COC Nonrandomized trial, Incidence of flare: 43% in COC 
50 µg ethynilestradiol non-placebo controlled groups, within 3 months of 
30 µg ethynil estradiol SLE female with nephropathy beginning OC
POC COC 50 µg: 14 No flare in POC group
COC 30 µg: 7
POC: 11
Julkunen, 199142 OC unspecified Retrospective study 31/85 had used OC after or
during SLE onset
4 (13%) noted a flare during
the first six months after 
starting OC
Incidence of flare was similar
as in patients not using OC
Buyon, 199541 OC unspecified Population survey 14% (n=55) were taking OC
after SLE diagnosis
Only 13% (n=7) self report
flare occurrence, mostly 
musculoskeletal
Petri et al, 200543 Triphasic OC (triphasic RCT-double blind No differences between 
ethinylestradiol 35 µg placebo-controlled, follow-up groups in occurrence of 
plus norethindrone at a 12 mo flares of any type
dose of 0.5 to 1 mg for 183 women with stable  
12 cycles of 28 days) or inactive disease
Sanchez et al, 200544 COC (35µg of ethinyl RCT-single blind, non-placebo. No difference among groups in 
estradiol plus 150µg of Follow-up 12 months mean activity, incidence of 
levonorgestrel) 162 SLE woman, ≤40 yo, flares or time to first flare
POC(30µ Levonorgestrel) with mild or stable disease
IUD (TCu 380A copper 
device)
NHS: Nurse Health Study; COC: Combined Oral Contraceptive; POC: Progestative Oral Contraceptive; IUD: Intra-Uterine Diaphragm
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Other Risks of OC in SLE patients
The estrogen component of combined OC increa-
ses hepatic production of serum globulines invol-
ved in coagulation, increases blood coaguability
and the risk of thrombotic events46. Case control
studies in the general population have shown an
increased risk of deep venous thrombosis and pul-
monary embolism associated to OC, ranging from
2.1 to 4.447, which is directly related to the dose of
estrogen and the type of progesterone. 
There is a high incidence of thromboembolic
events (TE) in SLE patients, particularly in those
with antiphospholipid antibodies (aPL)48-52, which
are common in SLE. Consequently, the decision of
OC use in SLE patients should consider the presen-
ce of aPL. Other risk factors for thrombotic events
recognized for general population as tobacco, ve-
nous insufficiency or other thrombophilic defects
should also be considered in SLE patients.
It is actually well recognized that SLE is associa-
ted with increased cardiovascular risk not explai-
ned by traditional risk factors. SLE patients pre-
sent more frequently high blood pressure. These
are particular issues to be considered when a OC
is prescribed to SLE patients. 
Other important point is the risk of infections.
SLE patients are commonly medicated with im-
munossupressive medications and at an increased
risk of infections. The use of IUD´s is associated
with an increased risk of infection in general po-
pulation. No studies with SLE female patients were
conducted to assess this issue, although studies
including patients with IUD´s found no increased
risk of infections in this group compared with
OC´s45,53. This potential infection risk should be ad-
dressed in SLE patients.
Practical advice: Which are the best options
for OC in SLE patients?
SLE presents a high incidence and prevalence
among women in childbearing age, which makes
the contraception an important issue to consider
in these patients. Estrogens have been considered
as having a deleterious effect in SLE patients, ba-
sed on animal and population studies as well as in
case reports. Despite case control studies have
shown no increased risk of SLE onset in patients re-
ceiving OC, more recent prospective studies de-
monstrate an increased risk, which is related with
type and dose of estrogens in OC. 
Prescription of OC in SLE patients should follow
the same recommendations given to the general
population54,55, with particular points related with
specific characteristics of this group of patients.
Although several studies have shown controver-
sial results related to an increased risk of flare
among OC users, two clinical trials show no in-
creased rate of flare in patients with inactive or sta-
ble disease receiving OC, without difference be-
tween combined OC, progestin-only OC or IUD.
No conclusions for patients with active disease are
possible from these studies, and consequently OC
in this group of patients should be avoided until
new data appear. 
Considering data for the general population, OC
are associated with an increased risk of thrombo-
tic events and its risk increases when thrombophi-
lia exists. Despite of theoretically combination OC
have higher risk of thrombotic events than Proges-
tin-only OC, both clinical trials found no differen-
ce of thrombotic events between them. Conside-
ring conditions in the general population where
OC are contraindicated in patients with higher
thrombophilic risk, this is a particular issue in SLE
patients, who commonly are aPL positive. So, in
SLE patients aPL should be evaluated before recei-
ving OC and if positive, combination OC should be
avoided. 
Despite all risks, use of OC has recognized be-
nefits in SLE patients as birth control, and poten-
tially may preserve ovarian function in SLE patients
Table III. Recommendations for Contraception use
in SLE patients
Contraception can be considered if:
1. Absolute and relative contraindications considered
for general population are not present53,54
2. Inactive or stable/moderate disease
3. No history of venous or arterial thrombosis
4. No high titer of any antiphospholipid antibody 
isotope 
5. No lupus anticoagulant
6. No-Smoker
7. Normotensive
For combined pill, use the lowest dose of 
ethynilestradiol (30-35 µg)
Consideration of pill containing progestin only
Considering risk of infection if intra-uterine ring use
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receiving cyclophosphamide. For all these reasons,
the possibility of OC use should be considered in
SLE patients and the decision should be taken ba-
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